Redeye provides a short research update following the positive phase Ib results with lead candidate ALZ-101 published by Alzinova last week. Overall, we are encouraged to learn that the candidate met the primary endpoint of safety and tolerability, while demonstrating a clear immunological response related to treatment. We raise our base case valuation to SEK12 (10) as we see an increased likelihood of approval (LoA) for ALZ-101 following the results.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Alzinova - Positive topline results

© Modular Finance, source Nordic Press Releases